Eucalyptus Bio


Eucalyptus Bio is a pre-clinical stage company which has developed a unique corrective long-range CRISPR based gene editing technology (CRISP-HR) that enables the treatment of diverse pathogenic casual mutations in genetic diseases with a single therapeutic molecule. We anticipate our platform will unlock hundreds of indications currently not addressable with other approaches and have already identified a handful of extremely high quality and exciting indications which we believe will demonstrate the tremendous power of our platform.


Get Involved with the Advanced Therapies Congress


To sponsor or exhibit

Ashlea Foster
+44 208 164 3032



To speak

Ila Dickinson
+44 207 092 1150